1. Combined effect of n-3 fatty acids and phytosterol esters on alleviating hepatic steatosis in non-alcoholic fatty liver disease subjects: a double-blind placebo-controlled clinical trial
- Author
-
Peng Ling Ouyang, Wen Juan Yu, Fengju Peng, Li Yang, Qi Guan, Xin Gang Zhao, Fei Yin, Wei Yan, Hongli Yan, Huanwang Du, and Lihua Song
- Subjects
medicine.medical_specialty ,Nutrition and Dietetics ,Chemistry ,Fatty liver ,Medicine (miscellaneous) ,Placebo ,medicine.disease ,Clinical trial ,Phytosterol esters ,Double blind ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Internal medicine ,Total cholesterol ,medicine ,030211 gastroenterology & hepatology ,N-3 fatty acids ,030212 general & internal medicine ,Steatosis - Abstract
The aim of this study was to investigate the combined effect of n-3 fatty acids (EPA and DHA, at an EPA:DHA ratio of 150:500) and phytosterol esters (PS) on non-alcoholic fatty liver disease (NAFLD) patients. We conducted a randomised, double-blind, placebo-controlled trial. Ninety-six NAFLD subjects were randomly assigned to the following groups: the PS group (receiving 3·3 g/d PS); the FO group (receiving 450 mg EPA + 1500 mg DHA/d); the PS + FO combination group (receiving 3·3 g/d PS and 450 mg EPA + 1500 mg DHA/d) and the PO group (a placebo group). The baseline clinical characteristics of the four groups were similar. The primary outcome was liver:spleen attenuation ratio (L:S ratio). The percentage increase in liver–spleen attenuation (≤1) in the PS + FO group was 36 % (P = 0·083), higher than those in the other three groups (PS group, 11 %, P = 0·519; FO group, 18 %, P = 0·071; PO group, 15 %, P = 0·436). Compared with baseline, transforming growth factor-β (TGF-β) was significantly decreased in the three study groups at the end of the trial (PS, P = 0·000; FO, P = 0·002; PS + FO, P = 0·001) and TNF-α was significantly decreased in the FO group (P = 0·036), PS + FO group (P = 0·005) and PO group (P = 0·032) at the end of the intervention. Notably, TGF-β was reduced significantly more in the PS + FO group than in the PO group (P = 0·032). The TAG and total cholesterol levels of the PS + FO group were reduced by 11·57 and 9·55 %, respectively. In conclusion, co-supplementation of PS and EPA + DHA could increase the effectiveness of treatment for hepatic steatosis.
- Published
- 2020
- Full Text
- View/download PDF